0001415889-12-000746.txt : 20120521 0001415889-12-000746.hdr.sgml : 20120521 20120521080020 ACCESSION NUMBER: 0001415889-12-000746 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120518 ITEM INFORMATION: Termination of a Material Definitive Agreement FILED AS OF DATE: 20120521 DATE AS OF CHANGE: 20120521 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Echo Therapeutics, Inc. CENTRAL INDEX KEY: 0001031927 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 411649949 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35218 FILM NUMBER: 12857072 BUSINESS ADDRESS: STREET 1: 8 PENN CENTER STREET 2: 1628 JFK BLVD, SUITE 300 CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: 215-717-4100 MAIL ADDRESS: STREET 1: 8 PENN CENTER STREET 2: 1628 JFK BLVD, SUITE 300 CITY: PHILADELPHIA STATE: PA ZIP: 19103 FORMER COMPANY: FORMER CONFORMED NAME: SONTRA MEDICAL CORP DATE OF NAME CHANGE: 20020702 FORMER COMPANY: FORMER CONFORMED NAME: CHOICETEL COMMUNICATIONS INC/MN/ DATE OF NAME CHANGE: 20020701 FORMER COMPANY: FORMER CONFORMED NAME: SONTRA MEDICAL CORP DATE OF NAME CHANGE: 20020701 8-K 1 form8k-05212012_080503.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 



CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of report (Date of earliest event reported):  May 18, 2012

 


Echo Therapeutics, Inc.

 (Exact name of Company as specified in its charter)

 


 

 

 

 

 

 

Delaware

 

000-23017

 

41-1649949

(State or other jurisdiction

of Incorporation)

 

(Commission File Number)

 

(I.R.S. Employer

Identification No.)

 

 

8Penn Center

1628 JFK Blvd., Suite 300

Philadelphia, PA

 



19103

(Address of principal executive offices)

 

(Zip Code)


Company’s telephone number, including area code: (215) 717-4100

 


 (Former name or former address, if changed since last report)

 



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 





Item 1.02.   Termination of a Material Definitive Agreement.


In response to shareholder feedback and concerns, on May 18, 2012, the Company notified MLV & Co. LLC (“MLV”) that it was terminating the At Market Issuance Sales Agreement (the “Sales Agreement”) between the Company and MLV dated as of May 9, 2012.  The termination is effective as of May 28, 2012.  No shares were sold under the Sales Agreement and the Company does not intend to sell any shares under the Sales Agreement prior to the termination date.





SIGNATURES

 

              Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

                                                                                   

ECHO THERAPEUTICS, INC.



Dated: May 21, 2012

By:  /s/  Patrick T. Mooney       

 

Patrick T. Mooney

 


President and Chief Executive Officer